Industry news that matters to you.  Learn more

Archives for April 2011

Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine

Myriad Genetics Inc. announced earlier this week that it has entered into a definitive merger agreement to acquire privately-held Rules-Based Medicine (RBM) of Austin, Texas for $80 million in cash. The deal expands Myriad’s research portfolio into new disease states, including psychiatric disorders, infectious diseases and inflammatory diseases, and adds eight new molecular diagnostic product candidates to Myriad’s already strong pipeline.

Biocortech, FondaMental Foundation Enter into a Strategic Alliance

Biocortech, the biotech company dedicated to the development of biological diagnostics for personalized psychiatry, and FondaMental, the foundation of scientific cooperation for mental health research and care, recently announced the signing of a strategic alliance to validate biomarkers for personalized psychiatry.

GVK Biosciences extends license of its Biomarker Database to the US FDA

GVK Biosciences (GVK BIO) announced that it has extended its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (USFDA). The GOBIOM database which has the latest and updated information on all the biomarkers reported in various clinical and preclinical studies will be of enormous use to USFDA in its Biomarker Qualification Process.

Boston Microfluidics Contracts Affinity Life Sciences for Immunoassay Development and Protein Chemistry Services

Boston Microfluidics, Inc. (BMF), a developer of a novel Point-of-Care (POC) device, and Affinity Life Sciences, Inc., a contract research and manufacturing organization specializing in biomarker assay development and protein chemistry services, have partnered to develop immunoassays and chemistry components related to Boston Microfluidics’ POC device.

Brain Imaging, Biomarker Studies Reflected in New Diagnostic Guidelines for Alzheimer’s Disease

Last week, new criteria and guidelines for diagnosing Alzheimer’s disease was released by the Alzheimer’s Association and the National Institute on Aging (NIA), and published online in the journal Alzheimer’s & Dementia. Long-term studies using brain imaging and biomarker analysis have demonstrated that physiological signs of Alzheimer’s disease begin long before the symptoms of dementia. The new guidelines reflect this growing pool of evidence, although they will have little immediate impact on patients as the tests used to identify Alzheimer’s at the earliest stages of disease aren’t ready for clinical use. Nevertheless, they should provide a framework for researchers and prepare clinicians for the day when more effective treatments become available.